Meridian Funds, managed by ArrowMark Partners, released its “Meridian Small Cap Growth Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the ...
Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today ...
DALLAS, July 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced the ...
Here's a quick look at what's been pushing up shares of Instil Bio and some of its challenges. Plus, I'll also measure the good news against the bad to see if everyday investors can reasonably expect ...
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
In January 2026, Axion Bio, Inc., a wholly owned subsidiary of Instil, discontinued clinical development of AXN-2510 and entered into a termination agreement with ImmuneOnco Biopharmaceuticals ...
Global registrational strategy in first-line triple-negative breast cancer (TNBC) Initiation of Phase 1b/2 IMM2510/SYN-2510 + chemotherapy combination in first-line NSCLC anticipated in late 2024 in ...
Stocktwits on MSN
Instil Bio Stock Soars After Jefferies Upgrade On 'Early Mover' Cancer Drug Candidate: Retail Jubilant
Instil Bio’s stock surged over 25% on Tuesday to levels last seen in early December after Jefferies upgraded the shares to ...
Summit Therapeutics' trial data drove stocks up by 150% for Summit, 40% for BioNTech and 500% for Instil Bio. Jefferies upgrades Instil Bio with a $52 target, forecasting over 300% upside from the ...
The Instil Bio Life Sciences Campus will be at 18404-18412 Oxnard Street in the neighborhood of Tarzana in the San Fernando Valley. CBRE said that, with clinical manufacturing operational, the recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results